The International Ki67 in Breast Cancer Working Group (IKWG) consensus recommended that Ki67 scores of 5% or less and 30% or more (but not 6%-29%) can be used for clinical decision making (2), whereas the widely used Predict online breast cancer decision aid (http://www.predict.nhs.uk) uses a 10% cutoff (5) and, for adjuvant abemaciclib treatment, a 20% cutoff has determined eligibility (6,7). The gene discussed is MKI67; the disease is breast carcinoma.